Advice

Strontium ranelate discontinued

In August 2017, due to limited demand, attributed to restrictions on its indication and additional monitoring requirements that followed a review by the European Medicines Agency of the risks and benefits of treatment, Les Laboratoires Servier, ceased the distribution of strontium ranelate (Protelos), for the treatment of osteoporosis in men at increased risk of fracture.

Medicine details

Medicine name:
Strontium ranelate 2g granules for oral suspension (Protelos®)
SMC ID:
178/05
Indication:
Postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures
Pharmaceutical company
Servier Laboratories Ltd
BNF chapter
Endocrine system
Submission type
Full submission
Status
Withdrawn
Date advice published:
08 August 2005